A new approach to COVID-19 treatmentWhile pharma has raced to develop COVID-19 vaccines, US-based company NeuroRx is taking a different approach to treating Share XA new approach to COVID-19 treatmenthttps://pharmaphorum.com/r-d/views-analysis-r-d/a-new-approach-to-covid-19-treatment/
Coordinating and delivering research in the pandemic: The UK approachThe acute phase of the COVID-19 pandemic tested the UK’s capacity and capability to rapidly deliver crucial clinical Share XCoordinating and delivering research in the pandemic: The UK approachhttps://pharmaphorum.com/webinars/uk-covid-coronavirus-research-nihr/
Resourceful or risky? The UK’s controversial COVID-19 vaccine strategyAs COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s Share XResourceful or risky? The UK’s controversial COVID-19 vaccine strategyhttps://pharmaphorum.com/r-d/views-analysis-r-d/resourceful-or-risky-the-uks-controversial-covid-19-vaccine-strategy/
The Alderley Park Discovery Podcast: Life science skills, staffing and supportEpisode two of the Alderley Park Discovery Podcast covers access to skills in the life sciences sector, with Share XThe Alderley Park Discovery Podcast: Life science skills, staffing and supporthttps://pharmaphorum.com/podcast/alderley-park-life-science-skills-staffing/
J&J and medical device innovation: the pharmaphorum podcastIn episode 27 of the pharmaphorum podcast I’m joined by Erin McEachren, who’s EU regional vice president at Share XJ&J and medical device innovation: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/johnson-medical-device-innovation/
Moderna and BioNTech – who are they?Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA Share XModerna and BioNTech – who are they?https://pharmaphorum.com/views-and-analysis/moderna-and-biontech-who-are-they/
Ardelyx’s ambition to revolutionise kidney treatmentA therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Share XArdelyx’s ambition to revolutionise kidney treatmenthttps://pharmaphorum.com/r-d/views-analysis-r-d/ardelyxs-ambition-to-revolutionise-kidney-treatment/
Tay-Sachs and rare disease registries – the Health Heroes podcastEpisode four of Kantar Health’s Health Heroes podcast tackles pharma’s rare disease challenges, the role of patient registries Share XTay-Sachs and rare disease registries – the Health Heroes podcasthttps://pharmaphorum.com/podcast/rare-disease-registries-kantar-health/
ABPI chief exec on the UK industry’s learnings from COVID-19The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 Share XABPI chief exec on the UK industry’s learnings from COVID-19https://pharmaphorum.com/views-analysis-market-access/abpi-chief-exec-on-the-uk-industrys-learnings-from-covid/
